| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
VU0360172 targets the metabotropic glutamate receptor 5 (mGlu5). It acts as a positive allosteric modulator (PAM), binding to an allosteric site on the receptor and enhancing the receptor's response to its endogenous agonist, glutamate. The compound is highly selective for mGlu5 with an EC₅₀ of 16 nM and a Ki of 195 nM.
|
|---|---|
| ln Vitro |
In vitro, VU0360172 acts as a potent and selective mGlu5 receptor positive allosteric modulator with an EC₅₀ of 16 nM and a Ki of 195 nM. It displays no significant activity at mGlu1, mGlu2, or mGlu4 receptors. The compound stimulates polyphosphoinositide (PI) hydrolysis in cells expressing mGlu5.
|
| ln Vivo |
In vivo, VU0360172 stimulates polyphosphoinositide (PI) hydrolysis, which is disrupted in mGlu5 receptor gene-deficient mice. The compound has shown potential in preclinical studies to reduce inflammation and impact conditions like inflammatory bowel disease (IBD) and asthma. Specific efficacy data and dosing regimens are limited.
|
| Enzyme Assay |
Non-cellular receptor binding assays for VU0360172 involve radioligand displacement using membrane preparations expressing the mGlu5 receptor. Membranes are incubated with a radiolabeled mGlu5 ligand and varying concentrations of VU0360172. Ki values are calculated from competition binding curves.
|
| Cell Assay |
In vitro cellular experiments involve cells expressing mGlu5 receptors. Cells are treated with VU0360172 at various concentrations in the presence of a submaximal concentration of glutamate. Receptor activation is measured by downstream signaling such as PI hydrolysis or calcium flux. EC₅₀ values for potentiation are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies involve rodent models of inflammation or other conditions. VU0360172 is administered via appropriate routes. PI hydrolysis is measured to assess target engagement. Inflammatory markers are measured to assess efficacy.
|
| ADME/Pharmacokinetics |
VU0360172 has a molecular weight of 294.32 g/mol and a molecular formula of C₁₈H₁₅FN₂O. It is soluble in DMSO. Storage: powder at -20°C.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for VU0360172 is limited. As a selective mGlu5 PAM, it is expected to have on-target effects related to glutamate signaling modulation. The compound is for research purposes only and should be handled with appropriate safety precautions.
|
| References | |
| Additional Infomation |
VU0360172 is a potent and selective positive allosteric modulator of the mGlu5 receptor with an EC₅₀ of 16 nM and a Ki of 195 nM. It displays no significant activity at mGlu1, mGlu2, or mGlu4 receptors. The compound stimulates PI hydrolysis in vivo. This product is for research purposes only and is not for human therapeutic use.
|
| Molecular Formula |
C18H15FN2O
|
|---|---|
| Molecular Weight |
294.32
|
| Exact Mass |
294.116
|
| CAS # |
1310012-12-4
|
| Related CAS # |
VU0360172 hydrochloride;1309976-62-2
|
| PubChem CID |
53318624
|
| Appearance |
Light yellow to brown solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
462
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(C1)NC(C1=CN=C(C#CC2C=CC=C(C=2)F)C=C1)=O
|
| InChi Key |
NEMHWVUKNWAKTM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H15FN2O/c19-15-4-1-3-13(11-15)7-9-16-10-8-14(12-20-16)18(22)21-17-5-2-6-17/h1,3-4,8,10-12,17H,2,5-6H2,(H,21,22)
|
| Chemical Name |
N-cyclobutyl-6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~283.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (7.07 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3977 mL | 16.9883 mL | 33.9766 mL | |
| 5 mM | 0.6795 mL | 3.3977 mL | 6.7953 mL | |
| 10 mM | 0.3398 mL | 1.6988 mL | 3.3977 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
